ABOS
NASDAQ
US
Acumen Pharmaceuticals, Inc. - Common Stock
$2,70
▲ +$0,15
(+5,88%)
Vol. 636K
3
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$127.8M
ROE
-97,4%
Margine
-509,7%
D/E
32,90
Beta
0,24
52W
$1–$2
Consenso Wall Street
12 analisti · Apr 20266
Acquisto forte
5
Compra
1
Mantieni
0
Vendi
0
Vendita forte
91,7%
Rating Compra
Grafico dei Prezzi
Titoli simili
PRLD
Prelude Therapeutics Inc
$164.2M
ARTV
Artiva Biotherapeutics Inc
$105.3M
RNAC
Cartesian Therapeutics Inc
$187.5M
WHWK
Whitehawk Therapeutics Inc
$114.1M
NKTX
Nkarta Inc
$131.4M
VTVT
vTv Therapeutics Inc
$167.1M
KALA
KALA BIO Inc
$12.2M
IMUX
Immunic Inc
$64.2M
TNYA
Tenaya Therapeutics Inc
$154.0M
HRTX
Heron Therapeutics Inc
$238.4M
Utili
Tasso di battuta: 60,0%
Prossimo report
Mag 11, 2026
Stima EPS: $-0,40
| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $-0,40 | — | — |
| Dic 2025 | $-0,46 | $-0,41 | +$0,05 |
| Set 2025 | $-0,62 | $-0,44 | +$0,18 |
| Giu 2025 | $-0,55 | $-0,68 | $-0,13 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Ricavi | — | — | — | — | — |
| Utile netto | -$29.8M | -$37.2M | -$28.8M | -$41.0M | -$26.5M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -81.4% | -81.4% | -81.4% | -81.4% | -97.4% | -97.4% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -509.7% | -509.7% | -509.7% | -509.7% | -509.7% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 25.52 | 25.52 | 25.52 | 25.52 | 32.90 | 32.90 |
| Current Ratio | 5.97 | 5.97 | 5.97 | 5.97 | 6.02 | 6.02 |
Rapporti chiave
ROA (TTM)
-70,4%
P/S (TTM)
88,76
P/B
0,6
EPS (TTM)
$-2,21
CF/Share
$-1,10
52W High
$2,46
52W Low
$0,86
$0,86
Intervallo 52 settimane
$2,46
Salute finanziaria
Flusso di cassa libero
-$30.5M
Debito netto
-$16.0M
Liquidità
$46.8M
Debito totale
$30.8M
Aggiornato al Set 30, 2025
Як ABOS виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка ABOS vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
88,8
▲
591%
sopra
peer
(12,9)
vs Peer
vs Settore
Più costoso
P/B
0,6
▼
77%
sotto
peer
(2,5)
vs Peer
vs Settore
Sottovalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість ABOS vs аналоги Biotechnology
ROE
-97,4%
▼
45%
sotto
peer
(-67,3%)
vs Peer
vs Settore
Debole
Net margin
-509,7%
▼
78%
sotto
peer
(-286,8%)
vs Peer
vs Settore
Debole
Валова маржа
—
▼
0%
sotto
peer
(78,6%)
vs Peer
vs Settore
In linea
ROA
-70,4%
▼
51%
sotto
peer
(-46,7%)
vs Peer
vs Settore
Debole
Фінансове здоровʼя ABOS vs аналоги Biotechnology
D/E ratio
32,9
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito alto
Поточна ліквідність
6,0
▲
36%
sopra
peer
(4,4)
vs Peer
vs Settore
Sotto media
Beta
0,2
▼
75%
sotto
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів ABOS
ABOS
Mediana peer
Industria
ABOS прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
ABOS vs аналоги: ключові метрики
Attività insider
NeutralAcquisti
0
Vendite
0
RA CAPITAL MANAGEMENT, L.P.
Beneficial Owner of more than… · Mar 16
6060606 shs
MEISNER DEREK M
Officer · Mar 06
2090 shs
MEISNER DEREK M
Officer · Mar 06
2090 shs
MEISNER DEREK M
Officer · Feb 27
9406 shs
MEISNER DEREK M
Officer · Feb 27
9406 shs
MEISNER DEREK M
Officer · Gen 28
17756 shs
MEISNER DEREK M
Officer · Gen 28
17756 shs
MEISNER DEREK M
Officer · Gen 23
8934 shs
WILLIAM MATTHEW ZUGA
Chief Financial Officer · Gen 22
4160 shs
O'CONNELL DANIEL JOSEPH
Chief Executive Officer · Gen 22
12035 shs
Ultimo 90 giorni
Principali azionisti
Top 5: 40,18%RA Capital Management, L.P.
24,65%
$33.7M
Sands Capital Alternatives,…
5,64%
$7.7M
Franklin Resources, Inc.
3,81%
$5.2M
FMR, LLC
3,35%
$4.6M
Vanguard Group Inc
2,73%
$3.7M
Aggiornato al Dic 31, 2025
Ultime notizie
Nessuna notizia correlata ancora